Novartis
19:45 :
Novartis finishes year with higher sales, lower profits -
Novartis AG, which employs 300 people under its vaccines division in
Holly Springs, reported fourth quarter and 2011 annual earnings late Wednesday. Despite increasing net sales by 16 percent to $58.6 billion, the Basel, Switzerland-based ...
10:35 :
Novartis falls 4% on MS drug concerns -
BOSTON (MarketWatch) -- Shares of Swiss drug maker Novartis AG fell 4% early Friday on reports that European regulators were looking into the cardiovascular safety of its recently approved multiple sclerosis treatment Gilenya. Shares of ...
12:54 :
Alcon Labs parent Novartis laying off 2,000 -
Swiss pharmaceutical giant Novartis AG announced Friday it would lay off 1,960 people and will take $1.22 billion in charges to prepare for generic competition to its blood pressure pill, Diovan, and lower sales potential of the drug Tekturna, ...
04:23 :
Novartis to Cut 1,960 Jobs -
Novartis said it will cut 1,960 jobs as it restructures its U.S. business, reflecting the patent loss of heart drug Diovan in the U.S. and the recent failure to turn high-blood pressure medicine Rasilez into a
blockbuster.
12:34 :
FDA: Novartis recall may also affect painkillers -
WASHINGTON (AP) -- The Food and Drug Administration is warning patients about a potential mix-up between powerful prescription pain drugs and common over-the-counter medications like Excedrin and Gas-X made at a Novartis manufacturing ...
16:41 :
Novartis to halt some sales of high blood pressure drug -
Two major pharmaceutical brands with ties to the D.C. region — Novartis and AstraZeneca — suffered some serious drug product setbacks recently Novartis has decided to halt sales of its approved high-blood pressure drug Rasilez, ...
02:44 :
Novartis preparing for pandemic -
HOLLY SPRINGS - Pharmaceutical giant Novartis on Monday declared its $1 billion vaccine production plant, the first such facility of its kind, ready to inoculate Americans against the next global pandemic outbreak.
10:42 :
Swiss stocks rally, led by Novartis, Roche -
LONDON (MarketWatch) -- The Swiss stock market rallied on Thursday, boosted by solid gains for pharmaceutical firms. The SMI index rose 1.3% to 5,728. Shares in drug firm
Roche Holding AG jumped 2.3%, while Novartis AG was ...
11:50 :
Novartis will not rule out Massachusetts layoffs -
Swiss drug maker Novartis AG (NYSE: NVS) announced Tuesday as part of its earnings release that the company would cut 2,000 jobs across U.S. and Swiss sites, while increasing head count by 700 in other, lower cost countries. A spokeswoman ...
10:11 :
Novartis to Slash 2,000 Jobs in Cost-Saving Plan -
The company attributed the gains to leading pipeline results in new approvals, such as its high blood pressure treatment Rasitrio and breast cancer drug Afinitor, which it says expands its ability to be patient needs and sustain long-term growth.
05:46 :
Novartis Cuts 2,000 as Pharma Industry Continues to Falter -
FRANKFURT (MarketWatch) -- Britain's House of Commons late Monday defeated a motion calling for a national referendum on Britain's membership in the European Union. The motion was expected to be defeated. The leadership of the Conservative, Liberal Democrat ...
01:52 :
Novartis gets European approval for Afinitor -
LONDON (MarketWatch) -- Swiss drug company Novartis AG said Monday that the European Commission has approved its Afinitor tablets for the treatment of neuroendocrine tumors of pancreatic origin. Novartis said the approval ...
actualidad Novartis -